A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The Motley Fool4d
Where Will Vertex Pharmaceuticals Be in 10 Years?
But it's logical to ask: What's Vertex's long-term story? Where will the company be in 10 years, for example? Let's find out. First, a bit of background on Vertex's CF program since it's so ...
Yahoo Finance19d
Vertex to Report Q4 Earnings: What's in Store for the Stock?
The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%. Vertex’s earnings surpassed the Zacks ...
The Business Journals25d
Vertex grew headcount 13% for the second straight year
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
The Boston Globe8d
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.